Trial Profile
A Phase II, Multi-Centre, Randomized, Double-Blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Bone metastases
- Focus Biomarker; Therapeutic Use
- Acronyms ZAMBONEY
- 04 Jun 2013 Primary endpoint 'Biochemical-response-rate' has not been met.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 27 May 2013 Status changed from active, no longer recruiting to completed.